Close Menu

NEW YORK (GenomeWeb) – Illumina plans to acquire Pacific Biosciences for approximately $1.2 billion in cash, the companies said on Thursday.

Under the agreement, which has been approved by both companies' boards of directors, Illumina will pay $8.00 per PacBio share, representing a 71 percent premium over PacBio's 30 trading-day volume weighted average share price as of the market close on Oct. 31, and a total value of about $1.2 billion on a fully diluted basis.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Three genetic testing companies form a coalition to influence how Congress considers genetic privacy, The Hill reports.

University of California, San Diego researchers investigate how skin care products influence the skin microbiome, Scientific American reports.

The Wall Street Journal examines billing codes used by uBiome.

In PNAS this week: links between lung adenocarcinoma and lncRNA, algorithm to impute and cluster Hi-C interaction profiles from single cells, and more.

Jul
23
Sponsored by
Qiagen

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 

Jul
30
Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.